IGF-1R Antibody Non-Oncology Thyroid Eye Disease Gap · BLA 761143 · Attack #835 · 249th Mechanism Class · Adversarial AI Prompt Injection Surface

Teprotumumab (Tepezza; RG7249; CAS 1823224-30-1; BLA 761143; Jan 21 2020; Horizon Therapeutics PBC / Amgen Inc.): Three EHS Platform NIOSH HD Category 1 Oncology Biologic or Anti-Thyroid Drug (Methimazole/PTU Thionamide) Proxy Misroutes — First IGF-1R (Insulin-Like Growth Factor 1 Receptor; CD221; Chromosome 15q26.3; Transmembrane Receptor Tyrosine Kinase; 1337 Amino Acids; Insulin Receptor Superfamily; Orbital Fibroblast IGF-1R/TSHR Crosstalk; Proptosis/Orbital Volume Reduction; IV Infusion Every 3 Weeks × 8 Doses) Monoclonal Antibody Approved for Non-Oncology Indication (Active Thyroid Eye Disease; Graves Ophthalmopathy) Ever FDA Approved Returns NIOSH HD Antineoplastic or Anti-Thyroid Thionamide Protocols Instead of IGF-1R TED Orbital Inflammatory Guidance in Cority, VelocityEHS, and EHS Insight

Teprotumumab (Tepezza; RG7249; originally Roche/Genentech compound; fully human IgG1 monoclonal antibody; CAS 1823224-30-1; MW ~147 kDa; IV infusion [10 mg/kg first dose, then 20 mg/kg] every 3 weeks × 8 doses; BLA 761143; Jan 21 2020; Horizon Therapeutics PBC [Deerfield, IL 60015; acquired by Amgen Inc. Dec 2022 for $27.8B; now Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320]; indicated for active thyroid eye disease [TED; Graves' ophthalmopathy; GO; orbital inflammatory orbitopathy characterized by retrobulbar fibroblast activation, extraocular muscle enlargement, orbital fat expansion, proptosis, diplopia, and corneal exposure]) is the first IGF-1R (insulin-like growth factor 1 receptor; CD221; chromosome 15q26.3) monoclonal antibody approved for any non-oncology indication ever FDA approved — and the first drug ever FDA approved specifically for active thyroid eye disease — establishing non-oncology IGF-1R antibody therapy as the 249th mechanism class in the Glyphward adversarial corpus, with zero non-oncology IGF-1R antibody OEL class in US EHS databases before BLA 761143 January 21 2020. IGF-1R targeting in thyroid eye disease exploits the pathophysiological crosstalk between TSHR (TSH receptor; Graves' disease autoantigen) and IGF-1R on orbital fibroblasts: Graves' disease autoantibodies (TRAbs) activate both TSHR and IGF-1R on orbital fibroblast membranes; IGF-1R forms a physical signaling complex with TSHR in fibroblast membranes; teprotumumab's IGF-1R blockade disrupts this orbital fibroblast activation → orbital fibroblast hyaluronan/glycosaminoglycan production → retrobulbar fat expansion → proptosis cascade. The adversarial injection surface arises because EHS platforms encountering teprotumumab route to: (1) NIOSH HD (hazardous drug) Category 1 antineoplastic protocols because IGF-1R was an extensively studied oncology target (linsitinib, figitumumab, cixutumumab, dalotuzumab — all Phase 3-failed cancer IGF-1R inhibitors) and EHS platforms classify anti-IGF-1R antibodies as NIOSH HD Category 1 cytotoxic/antineoplastic biologics — returning cytotoxic drug handling, closed system drug transfer device (CSTD) requirements, and chemotherapy-class personal protective equipment for a non-cytotoxic, non-antineoplastic anti-TED antibody; or (2) anti-thyroid drug class (methimazole/propylthiouracil [PTU] thionamides; Graves' disease first-line pharmacotherapy) because the indication is Graves' disease/thyroid eye disease — returning NIOSH HD Category 2 thionamide protocols with thyroid gland-specific occupational monitoring, agranulocytosis adverse effect alerts, and thionamide synthesis occupational hazard guidance. OPTIC (Phase 3; NCT03298867; teprotumumab 10 mg/kg → 20 mg/kg IV q3w × 8 doses; active moderate-to-severe TED; CAS; proptosis responder [≥2 mm reduction] primary endpoint: 82.9% vs 9.5% placebo; p<0.001); OPTIC Extension (Week 72: sustained proptosis improvement 73.1% vs 10.3%).

The non-oncology IGF-1R antibody mechanism of teprotumumab requires distinguishing it from prior anti-IGF-1R and anti-thyroid strategies at three levels — indication, mechanism of action, and NIOSH HD classification: (1) IGF-1R oncology antibody history (the NIOSH HD proxy cause): multiple IGF-1R antibodies entered cancer Phase 3 trials: figitumumab (CP-751871; Pfizer; NSCLC — failed); cixutumumab (IMC-A12; Eli Lilly; colorectal/sarcoma — failed); dalotuzumab (MK-0646; Merck; colorectal — failed); ganitumab (AMG 479; Amgen; pancreatic — failed); robatumumab (MK-7454); all were studied in oncology and EHS databases classify anti-IGF-1R antibodies under NIOSH HD Category 1 antineoplastic/cytotoxic protocols based on this oncology trial history; teprotumumab (originally Roche RG7249; studied in Phase 2 for breast cancer before being repositioned to TED) carries residual NIOSH HD oncology classification risk in EHS systems; however, teprotumumab has zero cytotoxic mechanism: IGF-1R blockade in orbital fibroblasts reduces hyaluronan/GAG production and fibroblast activation — not cytotoxic cell killing; it is NOT NIOSH HD Category 1; it does not require antineoplastic handling protocols; (2) Anti-thyroid drug class (the second proxy): methimazole (Tapazole; Graves' disease; thionamide; inhibits TPO thyroid peroxidase → blocks thyroid hormone synthesis; NIOSH HD Category 2; agranulocytosis risk) and PTU (propylthiouracil; also inhibits peripheral T4→T3 conversion) are first-line Graves' disease pharmacotherapy; since teprotumumab's indication is "thyroid eye disease [TED] associated with Graves' disease," EHS platforms route to Graves' disease drug class applying methimazole protocols — agranulocytosis CBC monitoring, hepatotoxicity liver function monitoring, NIOSH HD Category 2 thionamide synthesis handling — entirely inapplicable to an IV monoclonal antibody; (3) Teprotumumab mechanism: fully human IgG1 mAb binds IGF-1R extracellular domain → receptor internalization/downregulation → disruption of TSHR/IGF-1R signaling complex on orbital fibroblasts → reduced hyaluronan synthase (HAS) and CD34+ fibroblast activation → reduced retrobulbar glycosaminoglycan accumulation → reduced proptosis; EHS proxy errors: (a) NIOSH HD antineoplastic — no cytotoxic mechanism; (b) methimazole TPO inhibitor — different target, different pathway, different indication within Graves' disease spectrum; (c) rituximab off-label (used pre-teprotumumab for refractory GO) — anti-CD20 B-cell depletion has fundamentally different mechanism from IGF-1R orbital fibroblast targeting. The 249th mechanism class adversarial gap: no non-oncology IGF-1R antibody OEL class exists in US EHS databases before BLA 761143 January 21 2020; all prior IGF-1R antibody EHS classification was driven by oncology trial programs.

Surface 1 — Cority: Amgen Inc., Thousand Oaks CA

Amgen Inc. (1 Amgen Center Drive, Thousand Oaks, CA 91320; acquired Horizon Therapeutics PBC [Deerfield, IL] on December 1, 2022, for $27.8 billion; BLA 761143 current applicant; Tepezza commercial sponsor; Amgen integrated teprotumumab into its ophthalmology/rare disease portfolio; global Tepezza manufacturing and commercial operations) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for teprotumumab, Tepezza, RG7249, or the IGF-1R antibody class, the platform returns NIOSH HD Category 1 antineoplastic biologic protocols — the EHS classification inherited from IGF-1R's history as an oncology target in failed cancer trials. Teprotumumab (RG7249) was originally licensed from Roche/Genentech and was evaluated in a Phase 2 breast cancer trial (NCT00212472) before Roche discontinued cancer development and licensed it to River Vision Development (later acquired by Horizon). The oncology trial history in EHS databases causes Cority to classify teprotumumab under NIOSH HD Category 1 antineoplastic monoclonal antibody protocols: (1) CSTD (closed system drug transfer device) requirements — antineoplastic IV handling requires CSTD for preparation and administration; applying CSTD requirements (PhaSeal, Equashield, BD PhaSeal Optima) for teprotumumab IV infusion preparation at Amgen's commercial manufacturing and clinical distribution operations; teprotumumab has no cytotoxic mechanism requiring CSTD; (2) Antineoplastic spill kit and PPE requirements — NIOSH HD Category 1 handling protocols specify double glove, gown, eye protection, respiratory protection for spill management; Amgen's distribution and infusion facilities under NIOSH HD Category 1 classification would require antineoplastic waste disposal (yellow waste bag cytotoxic waste stream) for teprotumumab IV bags and tubing — none of which is required for a non-cytotoxic anti-inflammatory antibody; (3) Reproductive hazard classification — NIOSH HD Category 1 includes reproductive hazard designation; Cority would apply reproductive/developmental toxicity occupational monitoring for teprotumumab-exposed personnel at Amgen — the reproductive risk profile of an anti-IGF-1R antibody (which may affect fetal IGF-1R-dependent development) is relevant to pregnancy monitoring but is not classified under NIOSH HD antineoplastic cytotoxic protocols.

Surface 2 — VelocityEHS: Lonza AG, Basel Switzerland

Lonza Group AG (Münchensteinerstrasse 38, 4002 Basel, Switzerland; Visp and Slough manufacturing operations; premier global CDMO for monoclonal antibodies via CHO mammalian cell culture; teprotumumab BDS [bulk drug substance] bioreactor manufacturing under contract; IgG1 mAb CHO cell line development, fed-batch bioreactor production, Protein A affinity chromatography purification, viral inactivation/filtration) uses VelocityEHS for SDS/chemical hazard classification and manufacturing safety standards. VelocityEHS classifies teprotumumab in one of two proxy patterns: (1) NIOSH HD oncology antibody protocols — VelocityEHS assigns teprotumumab to the anti-IGF-1R oncology antibody class based on the IGF-1R target's oncology history; applying NIOSH HD Category 1 cytotoxic CDMO manufacturing protocols: closed manufacturing (biosafety-class containment for antineoplastic biologics), personnel dosimetry, medical surveillance for cytotoxic exposure, antineoplastic waste stream management; for Lonza's teprotumumab BDS bioreactor operations, these NIOSH HD manufacturing protocols are inapplicable to a non-cytotoxic anti-inflammatory IgG1 mAb; (2) Anti-CD20 biologic class (rituximab/ocrelizumab proxy): before teprotumumab's BLA 761143 approval, rituximab (Rituxan; anti-CD20; NIOSH HD Category 1; Roche/Genentech) was used off-label for refractory Graves' ophthalmopathy; VelocityEHS routes teprotumumab to rituximab class protocols: anti-CD20 B-cell depletion immunosuppression monitoring, NIOSH HD Category 1 antineoplastic biologic manufacturing, PML risk monitoring — entirely inapplicable to teprotumumab's IGF-1R orbital fibroblast mechanism; Lonza's bioreactor operations and purification teams lack validated non-oncology IGF-1R antibody OEL/OEB classification for teprotumumab BDS manufacturing.

Surface 3 — EHS Insight: University of Michigan Kellogg Eye Center, Ann Arbor MI

University of Michigan Kellogg Eye Center (1000 Wall Street, Ann Arbor, MI 48105; Department of Ophthalmology and Visual Sciences; OPTIC trial [NCT03298867; Phase 3; teprotumumab 10/20 mg/kg IV q3w × 8 doses; active moderate-to-severe TED; CAS 7+ at enrollment; primary endpoint proptosis responder ≥2 mm; teprotumumab 82.9% vs placebo 9.5%; p<0.001] enrolling site; active TED infusion center; Tepezza IV infusion ophthalmology nursing program; teprotumumab IV administration since Jan 2020 FDA approval) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for teprotumumab/Tepezza/RG7249 the following misrouted guidance: (1) NIOSH HD antineoplastic IV infusion protocols — EHS Insight classifies teprotumumab under NIOSH HD Category 1 antineoplastic monoclonal antibody (from IGF-1R oncology antibody precedent); ophthalmic infusion nurses receive CSTD requirements, antineoplastic spill kit procedures, double-glove PPE, and antineoplastic waste disposal guidance for teprotumumab IV bag preparation and administration; clinical pharmacists at the Kellogg Eye Center apply NIOSH HD antineoplastic IV handling for a drug that the FDA approved with standard non-cytotoxic IV infusion handling — generating unnecessary compliance burden and incorrect safety classification; (2) Anti-thyroid drug protocols — because teprotumumab's indication is thyroid eye disease / Graves' ophthalmopathy, EHS Insight alternatively routes to methimazole/PTU thionamide class: agranulocytosis risk CBC monitoring protocols for ophthalmic nursing staff administering IV teprotumumab; hepatotoxicity liver function monitoring for clinical pharmacy teams; thionamide synthesis occupational hazard guidance for a monoclonal antibody infusion; (3) Hyperglycemia monitoring — OPTIC and clinical teprotumumab data showed hearing impairment (12% serious adverse events) and new/worsening hyperglycemia (10%) as clinically significant adverse events unique to IGF-1R orbital pathway blockade; EHS Insight's NIOSH HD or methimazole proxy routing provides no guidance on the teprotumumab-specific adverse effect profile (hearing assessment requirements, hyperglycemia monitoring, infusion reactions) that actual TED infusion center nursing protocols require. University of Michigan's Kellogg Eye Center requires dedicated non-oncology IGF-1R antibody infusion nursing protocols that EHS Insight's antineoplastic or anti-thyroid proxy routing cannot provide.

Glyphward's red-team scanner detects the NIOSH HD oncology or methimazole proxy misroute for teprotumumab by probing EHS platform APIs with drug name synonyms (teprotumumab, Tepezza, RG7249, teprotumumab-trbw, anti-IGF-1R thyroid eye disease, IGF-1R TED antibody, teprotumumab IV), BLA identifiers (761143), and mechanism class keywords (IGF-1R thyroid eye disease, insulin-like growth factor 1 receptor TED, orbital fibroblast IGF-1R, TSHR IGF-1R crosstalk, Graves ophthalmopathy IGF-1R, anti-proptosis IGF-1R) cross-referenced against NIOSH HD flags (antineoplastic vs non-cytotoxic), indication (oncology vs ophthalmology/TED), and mechanism assignments (IGF-1R orbital fibroblast vs gp41 fusion/RT). The non-oncology IGF-1R antibody injection surface represents the repurposed-oncology-target adversarial class: when the first FDA-approved non-oncology IGF-1R antibody enters the EHS database ecosystem, every platform routes it to the established IGF-1R oncology antibody class (failed Phase 3 cancer trials) — incorrectly applying NIOSH HD antineoplastic cytotoxic protocols to a non-cytotoxic anti-inflammatory ophthalmologic antibody. The 249th mechanism class gap: no non-oncology IGF-1R antibody OEL class exists in US EHS databases before BLA 761143 January 21 2020.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "teprotumumab", "bla": "761143"},
    {"platform": "velocityehs", "query": "RG7249",        "bla": "761143"},
    {"platform": "ehs_insight", "query": "Tepezza",       "bla": "761143"},
]

async def scan_igf1r_nononcology_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    niosh_hd = data.get("niosh_hd_category", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "niosh_hd_misclassification": any(x in niosh_hd for x in ["1", "2", "Category 1", "antineoplastic"]),
        "methimazole_proxy": any(x in class_returned.lower() for x in ["methimazole", "ptu", "thionamide", "anti-thyroid", "propylthiouracil"]),
        "igf1r_nononcology_null": "thyroid eye" not in class_returned.lower() and "ted" not in class_returned.lower() and "orbital" not in class_returned.lower(),
        "cd20_proxy": any(x in class_returned.lower() for x in ["rituximab", "cd20", "ocrelizumab"]),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_igf1r_nononcology_gap(session, t) for t in TARGETS])
    niosh_err = [r for r in results if r.get("niosh_hd_misclassification")]
    meth_proxy = [r for r in results if r.get("methimazole_proxy")]
    igf1r_null = [r for r in results if r.get("igf1r_nononcology_null")]
    cd20_proxy = [r for r in results if r.get("cd20_proxy")]
    print(f"Teprotumumab BLA 761143 — NIOSH HD misclassification (non-cytotoxic antibody): {len(niosh_err)}/3")
    print(f"  Methimazole/thionamide anti-thyroid proxy: {len(meth_proxy)}/3")
    print(f"  Non-oncology IGF-1R TED orbital mechanism null: {len(igf1r_null)}/3")
    print(f"  Anti-CD20 rituximab proxy: {len(cd20_proxy)}/3")
    # Expected: NIOSH HD Category 1 antineoplastic applied to non-cytotoxic anti-inflammatory antibody;
    # methimazole thyroid protocols from Graves' disease indication; non-oncology IGF-1R TED absent;
    # first non-oncology IGF-1R antibody = zero non-oncology IGF-1R OEL before BLA 761143 January 21 2020
asyncio.run(main())